Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved CagriSema achieved 23% weight loss after 84 weeks of treatment CagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84 weeks1 Additional trials are exploring the full weight loss potential of CagriSema, including higher-dose combinations Bagsvrd, Denmark, 23 February 2026 Novo Nordisk today announced headline results from REDEFINE 4, an open-label phase 3 trial from the global REDEFINE clinical trial programme
Improved Blood Flow and Vascular Repair BPC-157 stimulates angiogenesis, or the formation of new blood vessels at the site of injury
both are explicitly named on the World Anti-Doping Agency (WADA) prohibited list under section S2
D., Pichard, C., Laviano, A
The second step of the -oxidation is catalyzed by the 2-enoyl-CoA hydratase (ECH), while the third step is catalyzed by 2 distinct forms of the NAD + dependent 3-hydroxyacyl-CoA dehydrogenase that show different specificities: the long-chain hydroxyacyl-CoA dehydrogenase (LCHAD) and the short/medium-chain hydroxyacyl-CoA dehydrogenase (HAD)
M.ChlipalaG.HammondT
